UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.

Pradalier A1, Lantéri-Minet M, Géraud G, Allain H, Lucas C, Delgado A.
CNS drugs.CNS Drugs.2004;18(15):1149-63.
INTRODUCTION: Seglor capsules, a unique modified-release formulation of dihydroergotamine mesilate, have long been in clinical use in France for migraine prophylaxis. The aim of the PROMISE (PROphylaxis of MIgraine with SEglor) study was to establish the efficacy and tolerability of Seglor in the pr
PMID 15581385

Rapoport AM1, Bigal ME, Tepper SJ, Sheftell FD.
CNS drugs.CNS Drugs.2004;18(10):671-85.
Intranasal medications for the treatment of headache have recently received increased attention. This paper reviews intranasal formulations of a variety of available medications (dihydroergotamine mesylate [dihydroergotamine mesilate], sumatriptan, zolmitriptan, butorphanol, capsaicin and lidocaine
PMID 15270595

van der Kuy PH1, Lohman JJ, Hooymans PM, Ter Berg JW, Merkus FW.
European journal of clinical pharmacology.Eur J Clin Pharmacol.1999 Nov;55(9):677-80.
OBJECTIVE: A comparison of the pharmacokinetic properties of two novel intranasal preparations of dihydroergotamine mesilate (DHEM) with a commercially available intranasal preparation.METHODS: Two intranasal formulations of DHEM in combination with randomly methylated beta-cyclodextrin (RAMEB) were
PMID 10638398